Patient value: its nature, measurement, and role in real world evidence studies and outcomes-based reimbursement

被引:15
|
作者
McKenna, Stephen P. [1 ,2 ]
Wilburn, Jeanette [1 ]
机构
[1] Galen Res Ltd, B1 Chorlton Mill,3 Cambridge St, Manchester M1 5BY, Lancs, England
[2] Univ Manchester, Sch Hlth Sci, Manchester, Lancs, England
关键词
Health-related quality-of-life; health service evaluation; needs-based quality-of-life; outcomes-based reimbursement; patient reported outcome measures; patient value; real world evidence; QUALITY-OF-LIFE; HEALTH; PSORIASIS; PSORIQOL; SCORES;
D O I
10.1080/13696998.2018.1450260
中图分类号
F [经济];
学科分类号
02 ;
摘要
The assessment of patient value is fundamental to clinical trials, real world evidence studies, and outcomes-based reimbursement schemes. Measures of health-related quality-of-life (HRQoL) are widely used in health research. Such measures are effective in determining the presence or absence of symptoms and functional ability. However, HRQoL measures were not intended, nor designed, to determine the value to patients of alternative health states. Functions have no intrinsic value-they are a means to fulfil human needs. However, needs can be met in a variety of ways, for example by adopting different functions or by the provision of social services. It is possible to analyze all functions in terms of the needs they satisfy. A needs model has been applied in health research since the 1990s. It is concerned with the extent to which human needs are fulfilled in the presence of disease and its treatment. It is argued that this is the major concern of the patient. Needs-based measures are patient-centric and produce a valid unidimensional index of outcome. Consequently, they provide a direct means of measuring patient value. This approach provides the possibility of evaluating health services in terms of the value they provide to consumers and payers. It also has a role to play in real-world evidence studies and outcomes-based reimbursement. It is recommended that greater attention is given in future to the development of patient-reported outcome measures that provide direct assessments of patient value.
引用
收藏
页码:474 / 480
页数:7
相关论文
共 50 条
  • [21] XERMELO Patient Registry: A Real-World Evidence Study Evaluating Patient-Reported Outcomes With XERMELO
    Joish, Vijay N.
    Price, Mark A.
    Schwartz, Steven
    Stanley, Shanna
    Bennett, Lee
    Darden, Christina
    Tesfaye, Eshetu
    Mobley, Quintella
    Arnold, Karie
    Wason, Suman
    Lapuerta, Pablo
    PANCREAS, 2019, 48 (03) : 439 - 439
  • [22] TRANSLATING CLINICAL OUTCOMES TO PATIENT VALUE - AN EVIDENCE-BASED TREATMENT APPROACH
    LEVINE, RA
    SHANAMAN, RH
    INTERNATIONAL JOURNAL OF PERIODONTICS & RESTORATIVE DENTISTRY, 1995, 15 (02) : 187 - 200
  • [23] EXPLORING THE ROLE OF OUTCOMES RESEARCH IN DUTCH REIMBURSEMENT POLICY: REAL-WORLD PHARMACOECONOMICS OF OXALIPLATIN IN STAGE III COLON CANCER
    van Gils, C. W. M.
    Redekop, W. K.
    Punt, C. J. A.
    Uyl-de Groot, C. A.
    VALUE IN HEALTH, 2009, 12 (07) : A258 - A258
  • [24] The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
    Lee, Dawn
    Brereton, Nic
    Dhanasiri, Sujith
    Kulasekararaj, Austin
    PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 351 - 358
  • [25] Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement
    Peasah, Samuel K.
    Huang, Yan
    Palli, Swetha R.
    Swart, Elizabeth C. S.
    Donato, Bonnie M. K.
    Pimple, Pratik
    Bovier, Jacqueline
    Manolis, Chronis
    Good, Chester B.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (02): : 152 - 160
  • [26] The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
    Dawn Lee
    Nic Brereton
    Sujith Dhanasiri
    Austin Kulasekararaj
    PharmacoEconomics - Open, 2019, 3 : 351 - 358
  • [27] Efficacy of Dapagliflozin and Its Role on Microalbuminuria: Multicentric Real World Evidence from Pakistan
    Wahab, M. U.
    Kalra, S.
    Aisha, U.
    Raja, U. Y.
    Ahmad, I.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [28] Real-world adherence to erenumab, rescue medication utilization, and work absenteeism for patients with migraine: Results from an outcomes-based agreement
    Swart, Elizabeth C. S.
    Peasah, Samuel K.
    Huang, Yan
    Bensink, Mark E.
    Greco, Melissa S.
    Manolis, Chronis
    Good, Chester B.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (03): : 236 - 244
  • [29] Making real-world studies relevant to evidence-based decisions
    Lyles, A
    CLINICAL THERAPEUTICS, 2005, 27 (07) : 1090 - 1091
  • [30] Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
    Gerds, Aaron T.
    Yu, Jingbo
    Scherber, Robyn M.
    Paranagama, Dilan
    Kish, Jonathan K.
    Visaria, Jay
    Singhal, Mukul
    Verstovsek, Srdan
    Pemmaraju, Naveen
    ACTA HAEMATOLOGICA, 2022, 145 (04) : 448 - 452